Study provides new insights into the role of aging in heart failure

Medical Xpress | March 06, 2019

A team led by Massachusetts General Hospital (MGH) investigators has found that activity of an important signaling pathway increases with aging and with heart failure. In their report published in Science Translational Medicine, they describe evidence from both humans and animal models that increased activin type II receptor (ActRII) activity correlates with worsening heart failure and that inhibiting ActRII can improve cardiac function in mouse models. "Age has long been recognized as one of the major, if not the dominant, risk factor for heart disease, but why is not well known," says Jason Roh, MD, of the Corrigan Minehan Heart Center at MGH, lead author of the report. "Our findings suggest that the ActRII pathway plays a major role in the intersection between aging and heart disease and that inhibiting it could offer much-needed new treatment strategies for heart failure, a deadly disease that is also the number one cause of hospitalization for older adults."

Spotlight

In this "how-to" video, users of the ImageXpress Micro System will learn ways to adjust the correction collar on the objective to accommodate for different plate bottom or slide thicknesses, thus ensuring optimal image quality.

Spotlight

In this "how-to" video, users of the ImageXpress Micro System will learn ways to adjust the correction collar on the objective to accommodate for different plate bottom or slide thicknesses, thus ensuring optimal image quality.

Related News

RESEARCH

PostEra announces $260M multi-target strategic AI Lab collaboration with Pfizer

PostEra | January 12, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's data, and PostEra's pioneering innovations in generative chemistry and synthesis-aware design. PostEra will receive an upfront payment of $13M and is eligible to receive additional milestone payments totalling up to $248M should all milestones be achieved, in addition to tiered royalties on any approved products arising out of the collaboration. The AI Lab will tightly integrate drug discovery with technology development to ensure a continuous feedback loop that refines both the process and predictions from the platform. The vision of the AI Lab is to combine Pfizer's expertise and data with PostEra's technology to advance these drug discovery programs, while also producing an integrated state-of-the-art platform to be deployed across Pfizer's in-house, preclinical drug discovery efforts. "We think the best way to build leading technology is to have its development tightly integrated with live drug discovery programs", said Dr. Alpha Lee, Chief Scientific Officer of PostEra. "We're pleased that we are expanding the existing collaboration to do exactly this and to reap the AI advantage in improving preclinical drug discovery," Aaron Morris, CEO of PostEra "At Pfizer, we believe digital technologies, including artificial intelligence and machine learning, hold great potential to aid the discovery of novel approaches to prevent, cure, and treat disease for patients in need," said Charlotte Allerton, Head of Medicine Design, Pfizer. "We're excited to extend our collaboration with PostEra to further build on our current capabilities." The company today also announced its $24M Series A financing. The new funding will enable PostEra to further expand its partnered drug discovery programs, initiate internal drug discovery programs, as well as further develop its AI-first medicinal chemistry platform. About PostEra PostEra was founded in 2019 and its technology is built on pioneering academic research done by its founding scientists. PostEra's technology addresses some of the key challenges in drug discovery R&D by integrating molecular design with chemical synthesis. PostEra advances small molecule programs through partnerships with biopharma, working on its own internal pipeline, and also offering some of its synthesis technology via its Manifold web platform. PostEra also launched and now helps lead the world's largest open-science drug discovery effort; COVID Moonshot.

Read More

Emergent BioSolutions Announces Initiation of Phase 3 Cinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19 Patients

Emergent BioSolutions | October 09, 2020

NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19. Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure. Emergent BioSolutions, Inc. Inc. (NYSE:EBS) today announced the initiation of the Phase 3 clinical trial that will evaluate plasma-derived therapy COVID-HIG as a potential treatment for hospitalized patients with coronavirus disease (COVID-19). The INSIGHT-013 clinical study called “Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC),” is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study will evaluate the safety, tolerability, and efficacy of hyperimmune globulin products derived from plasma of individuals who have recovered from COVID-19 and have developed neutralizing antibodies to SARS-CoV-2, the virus that causes COVID-19. The randomized controlled clinical trial assigns participants to receive infusions of either a placebo or one of four hyperimmune globulin products, which includes Emergent’s COVID-HIG, with a background therapy of remdesivir in all groups.

Read More

MEDICAL

Stramsen Biotech, Inc. to Fund Next Phases of Clinical Trials and Additional Medicine Discovery Research

Stramsen Biotech, Inc | December 17, 2020

Stramsen Biotech, Inc, a professional group of medication researchers from the Houston, Texas territory comprises of scientists who devote their lives each day to investigating and exploring both the cycles and logical instruments hidden the world we live in today. Colleagues have gotten a few honors and awards for research ventures, with a significant number of their activities and distributions accessible upon demand. Individuals incorporate PhD and University level professors who specialize in chemistry, medication and different biotechnology research projects. This group of experienced researchers has been included widely in clinical examination for more than 20 years. Stramsen Biotech, Inc has more than six drug/medicine candidates currently in early-stage clinical trials. Two drug/medicine candidates have demonstrated promising outcomes in early clinical preliminaries for treatment of HIV/AIDS. A third drug applicant has additionally demonstrated promising outcomes in early clinical preliminaries for treatment of numerous kinds of wounds and cuts, including diabetic injuries. A fourth medication applicant shows promising outcomes in early clinical preliminaries for treating the basic Flu and Covid-19. The fifth outstanding medication competitor, focusing on ongoing and advance stage malignant growths, has additionally indicated promising outcomes in early clinical preliminaries. Finally, a 6th applicant as an immunization shows promising clinical preliminary outcomes for Newcastle disease, a infection of domestic poultry and other winged creature species with the virulent Newcastle disease virus (NDV).

Read More